Udenyca: how international patients access US-sourced specialty supply

This page is informational, not medical advice. Always work with a licensed treating physician on prescribing decisions. Reserve Meds does not make insurance or pharmacy-assistance-program promises.

Quick orientation

Udenyca (pegfilgrastim-cbqv (biosimilar)) is sponsored by Coherus BioSciences and received first US FDA approval in 2018. It is delivered as subcutaneous injection, once per chemotherapy cycle. The US label covers reduction of the incidence of infection (manifested as febrile neutropenia) in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy associated with a clinically significant incidence of febrile neutropenia. Mechanistically, Udenyca is a biosimilar to pegfilgrastim, a PEGylated recombinant granulocyte colony-stimulating factor (G-CSF).

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

US wholesale acquisition cost (WAC) is the published US specialty-distribution list price and is not the same as a single-payer negotiated price. US WAC for Udenyca runs materially below originator Neulasta, commonly in the USD 3,000 to USD 4,500 per single-dose range. Patient out-of-pocket via cross-border supply is the US WAC plus logistics, IOR / customs, translation, and a Reserve Meds concierge fee; it is not a route to local-formulary pricing.

Mechanism of action

Udenyca is a biosimilar to pegfilgrastim, a PEGylated recombinant granulocyte colony-stimulating factor (G-CSF). PEGylation extends serum half-life so that a single SubQ injection per chemotherapy cycle drives neutrophil recovery, replacing daily filgrastim injections in the post-chemotherapy nadir window.

Why Udenyca routes via cross-border NPP internationally

Pegfilgrastim biosimilar landscape varies markedly by country. In several MENA and South Asian markets, oncology pharmacies stock originator Neulasta at high local cost or stock different biosimilars; Udenyca is sometimes specifically prescribed for consistency, prior tolerance, or cost discipline within a multi-cycle chemotherapy plan, and is then imported on a named-patient basis.

The patterns that produce cross-border demand for Udenyca are consistent across destination countries: meaningful registration lag relative to the US label, indication-specific dosing complexity that makes substitution clinically risky, payer denial patterns that exclude newer or expanded indications, and the global specialty distribution model in which the originator manufacturer routes specialty supply through a small number of authorized US wholesalers. Reserve Meds sits inside that authorized supply lane, not outside it.

How Reserve Meds coordinates supply

Every Udenyca case follows the same physician-led, document-first workflow:

1. The treating physician issues a prescription and clinical justification letter.
2. Reserve Meds clinical and regulatory review assesses indication fit and destination-country pathway eligibility.
3. Country-specific named-patient or personal-import documentation is prepared, translated where required, and submitted to the destination-country regulator under the local lawful import framework.
4. Supply is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability (a federal track-and-trace requirement) and unbroken chain of custody from US warehouse forward.
5. Cold-chain handling is validated where applicable; temperature is monitored end-to-end with audit logs.
6. Shipment is coordinated to the patient's treating physician or hospital pharmacy, not directly to consumers.

Reserve Meds does not handle controlled substances. We do not promise pharmacy assistance program enrollment, manufacturer copay support, or insurance reimbursement; those are different commercial frameworks aimed at US-domiciled patients.

Common cross-border destinations

Udenyca cross-border demand concentrates in markets where US specialty supply is the most reliable path to the labeled indication. We publish destination-country deep-dives where local matrix cells exist; the rest are coordinated case-by-case on the same physician-led workflow.

Across each of these destinations, three structural patterns repeat. First, the local regulator maintains a named-patient or personal-import framework precisely so clinicians can reach a labeled US therapy for individual patients whose case cannot wait for full local registration. Second, that framework is document-driven, which means the work of cross-border access is the work of preparing a defensible clinical and regulatory dossier rather than chasing inventory. Third, the destination-country specialist (the treating physician) signs the case in; Reserve Meds operates on top of that signature, not in place of it.

Real cost picture

Drug-only cost at US WAC commonly runs USD 3,000 to USD 4,500 per single dose; for a typical 4 to 8 cycle chemotherapy plan, total drug cost is in the low five figures. Cold-chain logistics applies. Reserve Meds quotes firm pricing post-document review.

A formal Reserve Meds quote breaks out: drug cost at US WAC; cold-chain 3PL handling where applicable; IOR, customs, and destination-country regulatory fees; certified translation of physician documentation; and a tiered Reserve Meds concierge fee layered on the drug cost rather than per-dose. The indicative range above is for orientation; a firm quote is issued after physician documentation is reviewed.

Reserve Meds does not charge intake deposits. Patients pay the firm-quoted amount in full only after accepting the quote, with a defined refund posture for procurement failure or gross negligence as set out in the engagement documentation. Delivery or transit-failure outcomes are handled via insurance and replacement coordination rather than refund, because once a US procurement chain is committed, the drug is committed.

Manufacturer context and global distribution

Udenyca is manufactured by Coherus BioSciences. Like most US specialty therapies, it is routed through a narrow set of authorized specialty wholesalers under DSCSA (Drug Supply Chain Security Act) track-and-trace rules. That is the same supply lane US specialty pharmacies use; cross-border named-patient access works by attaching destination-country regulatory documentation to a shipment that originates inside that authorized lane, not by sourcing outside it. Counterfeit and parallel-trade exposure is concentrated outside that lane, which is precisely why Reserve Meds will not source from secondary or grey-market channels regardless of price.

Serial-number traceability is preserved end-to-end. Every Udenyca pack or vial carries the US wholesaler's lot and serial-number documentation forward into the destination-country regulatory submission, which is what allows the destination regulator to verify provenance on inspection.

What your physician provides

For Reserve Meds to coordinate Udenyca, the treating physician provides an oncologist prescription, a clinical justification letter documenting the underlying non-myeloid malignancy, the chemotherapy regimen and its febrile-neutropenia risk classification, a bone-pain / splenic-rupture-awareness counseling note, and license verification. Reserve Meds does not substitute for treating-physician judgment, does not prescribe, and does not advise on individual patient suitability; that is the treating physician's role.

Common questions

Is Udenyca clinically equivalent to Neulasta?

Udenyca is a US FDA-approved biosimilar to pegfilgrastim; FDA biosimilar approval is built on demonstrated equivalence in efficacy, safety, and immunogenicity.

How is it different from daily filgrastim?

PEGylation extends half-life so one SubQ injection per cycle replaces multiple daily filgrastim injections.

When in the cycle is it given?

Typically about 24 hours after chemotherapy administration; do not co-administer with chemotherapy.

Does it require cold chain?

Yes. Refrigerated storage.

Is it appropriate for myeloid malignancies?

The pegfilgrastim label is specifically for non-myeloid malignancies; use in myeloid disease is specialist-directed only.

Indicative timing

Time-to-first-dose for Udenyca is dominated by destination-country regulatory turnaround on the named-patient or personal-import submission, not by US procurement (which is typically days, not weeks, for an authorized specialty wholesaler with serialized stock). In faster markets (UAE Ministry of Health and Prevention named-patient track, Saudi SFDA named-patient track), the regulatory clock is commonly under 4 weeks when the dossier is complete on first submission. In slower markets or where translations and additional attestations are required, the regulatory clock can extend to 6 to 10 weeks. Reserve Meds frames every Udenyca timeline as an indicative range with a defined gating event (regulator acknowledgement), not as a guaranteed delivery date.

Subsequent cycles are materially faster than the first cycle because the regulatory file, physician credentials, and import authorization are already on record. For chronic-use therapies like Udenyca, the first cycle carries the regulatory overhead; the rest is logistics.

Where Reserve Meds fits in

Reserve Meds is the named cross-border coordinator. A dedicated patient coordinator owns the case from intake through delivery, the clinical and regulatory teams handle the document chain, and a DSCSA-compliant specialty wholesaler is the source of every vial or pack. We work in service of the treating-physician relationship, not around it.

Patients deal with one named coordinator from intake through delivery. Physicians deal with a clinical-and-regulatory contact who speaks the language of the destination regulator and of US specialty pharmacy. That single-point-of-contact structure is deliberate: cross-border specialty access fails most often at the seams between parties, not inside any single step, and Reserve Meds is built to own the seams.

Next step

Submit a 60-second intake. Our clinical team will respond as our first cohort opens with case-specific feasibility, a country pathway, an indicative timeline, and a formal quote.

Start your case Or message us on WhatsApp